About the Authors
- Harriette R. Mogul
-
* E-mail: hrmogul@NYMC.edu
Affiliation Department of Medicine, Division of Endocrinology, New York Medical College, Valhalla, New York, United States of America
- Ruth Freeman
-
Affiliation Departments of Medicine and Obstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, New York, United States of America
- Khoa Nguyen
-
Affiliation Department of Medicine, Division of Endocrinology, New York Medical College, Valhalla, New York, United States of America
- Michael Frey
-
Affiliation Department of Medicine, Division of Endocrinology, New York Medical College, Valhalla, New York, United States of America
- Lee-Ann Klein
-
Affiliation Department of Medicine, Division of Endocrinology, New York Medical College, Valhalla, New York, United States of America
- Sheila Jozak
-
Affiliation Departments of Medicine and Obstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, New York, United States of America
- Karen Tanenbaum
-
Affiliation Department of Medicine, Division of Endocrinology, New York Medical College, Valhalla, New York, United States of America
Competing Interests
EMPOWIR (NCT00618072) is an unsolicited, investigator-initiated study partly supported by Glaxo Smith Kline. The Rosiglitazone (trade name Avandia) used in this study is a Glaxo Smith Kline product. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: HRM RF LK. Performed the experiments: HRM RF MF SJ KT LK. Analyzed the data: HRM RF MF KN. Contributed reagents/materials/analysis tools: HRM MF RF. Contributed to the writing of the manuscript: HRM RF LK KN.